Atrial fibrillation has quietly become the leading cause of stroke in adults over 65. Roughly 40 percent of strokes in older adults are now attributable to AFib, and a stroke caused by AFib is on average more severe, more disabling, and more likely to be fatal than a stroke from any other cause. The reason is straightforward: when the upper chambers of the heart quiver instead of contracting, blood pools and forms clots, and those clots travel in large pieces directly to the brain.
The harder fact is that most people with AFib do not know they have it. The condition is often intermittent, the symptoms are easy to dismiss, and the standard 12-second EKG done at a primary care visit catches it only by accident. By the time many patients are diagnosed, the diagnosis is made retrospectively from the hospital stroke unit.
This is preventable. Here is what every patient over 60 should know.
The three symptoms patients almost always dismiss
The textbook AFib symptom is palpitations, a sensation that the heart is fluttering, racing, or skipping. About a third of AFib patients describe this. The remaining two-thirds either feel nothing at all or describe symptoms that are easy to attribute to other causes.
The most commonly missed symptom is fatigue. Patients describe new exercise intolerance, needing to sit down after climbing one flight of stairs that they previously climbed without thought, or losing the energy to finish errands they used to complete easily. The heart in AFib pumps less efficiently because the upper chambers are not contributing to ventricular filling, and the resulting reduction in cardiac output presents as fatigue rather than chest discomfort.
The second commonly missed symptom is shortness of breath on exertion. New or worsening dyspnea, especially when bending forward or lying flat, can be the first clinical sign of AFib-related heart failure.
The third is unexplained dizziness or near-fainting episodes, particularly when standing up quickly.
Why your CHA2DS2-VASc score matters
Once AFib is diagnosed, the most important number is not the heart rate. It is the CHA2DS2-VASc score, a simple risk calculator that estimates annual stroke risk based on six factors: congestive heart failure, hypertension, age over 75 (worth two points), diabetes, prior stroke (worth two points), vascular disease, age 65 to 74, and female sex.
A score of zero in a man or one in a woman generally does not require anticoagulation. Any higher score does. For a typical 70-year-old Texan with hypertension and diabetes, the annual stroke risk without anticoagulation is roughly 5 to 7 percent per year. With anticoagulation, that drops by about two-thirds. Over a decade, the difference is enormous.
The modern treatment ladder
Rate control comes first. The goal is to keep the heart rate under 110 beats per minute most of the time, usually with a beta-blocker or calcium channel blocker. For many older patients with permanent AFib, rate control alone is sufficient.
Rhythm control is the second tier. For patients who are highly symptomatic, who have heart failure, or who are younger and want to restore normal rhythm, antiarrhythmic medications can convert and maintain sinus rhythm.
Cardioversion is a same-day in-office or outpatient procedure that delivers a synchronized electrical shock under brief sedation to restore normal rhythm in patients in persistent AFib. It is usually combined with antiarrhythmic medication to maintain the rhythm after conversion.
Catheter ablation is referred out to electrophysiology and is increasingly first-line for younger or highly symptomatic patients. Modern pulmonary vein isolation has success rates between 70 and 85 percent for paroxysmal AFib.
Modern anticoagulation: why DOACs replaced warfarin
The biggest change in AFib care in the last decade has been the shift from warfarin to direct oral anticoagulants, or DOACs. Apixaban, rivaroxaban, dabigatran, and edoxaban all provide stroke protection at least as good as warfarin without the dietary restrictions, the monthly blood tests, or the constant dose adjustments. For most patients, DOACs are now strongly preferred.
There are still specific scenarios where warfarin remains the right choice — mechanical heart valves, moderate to severe mitral stenosis, and severe kidney impairment among them — but for the typical 70-year-old with AFib and no contraindication, a DOAC is the modern standard of care.
When intermittent AFib won’t show up on testing
A common frustration: a patient describes occasional palpitations, the EKG in the office is normal, the 24-hour Holter monitor catches nothing, and AFib remains undiagnosed for years. The solution is the implantable loop recorder, a small device placed just under the skin of the chest that continuously monitors heart rhythm for up to three years. For patients with cryptogenic stroke or unexplained intermittent symptoms, loop recorders catch AFib in a substantial percentage of cases that all other monitoring missed.
When to ask for a specialist referral
Any patient with newly diagnosed AFib should be seen by a cardiologist within 30 days. Patients with persistent symptoms despite rate control, patients under 65 wanting rhythm control, patients on warfarin who could be candidates for a DOAC switch, and patients with intermittent symptoms not captured by short-term monitoring all benefit from specialist evaluation.
For Texas patients in Montgomery County or the greater North Houston area, an atrial fibrillation specialist in The Woodlands with on-site echocardiography, Holter monitoring, loop recorder placement, and cardioversion capability is the most efficient single point of care.
The bottom line: AFib is common, often silent, and dramatically responsive to modern treatment. Patients who get diagnosed and treated early avoid the catastrophic stroke that defines the disease for those who do not.